

# R H I N O M E D

## BOARD CHANGE

**16 October 2023: Melbourne, Australia.**

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, announces that Mr Brent Scrimshaw, Non-Executive Director, will retire from the Board of Directors effective from November 17th, 2023.

Mr Scrimshaw was appointed to the board on the 12th of February 2014. Since that time he has served the company as it began commercialising its technology and brands across the Australian, US and UK consumer health markets.

Rhinomed's CEO and MD Mr Michael Johnson commented, "Brent has played a vitally important role as we have built Mute into one of the leading solutions in the global sleep and snoring market. I would personally like to thank Brent for his support, guidance and contribution to the company and wish him the best in the future."

Rhinomed's Chairman Mr Ron Dewhurst said, "The role Brent has played was instrumental in forging Rhinomed's presence across our global markets. It has been a pleasure working with Brent as a board member since joining the company and on behalf of all Directors and Staff of Rhinomed we wish Brent every success moving forward."

This report has been authorised for release to the market by the Board.

| Company   | Investor and Media Relations   |
|---|--|
| Michael Johnson,<br>CEO & Director<br>+61 (0) 3 8416 0900<br><a href="mailto:mjohnson@rhinomed.global">mjohnson@rhinomed.global</a><br>Follow us on <b>Twitter</b> @rhinomedceo | Rudi Michelson<br>Monsoon Communications<br>+61(0) 411 402 737<br><a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a> |

### **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.